Related Experiment Video
Updated: Jun 6, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Assessment of DBS technology for the detection of therapeutic antibodies
Peter J Prince1, Katherine C Matsuda, Mw Retter
1Pharmacokinetics and Drug Metabolism (PKDM), Amgen Inc., 1201 Amgen Court West, Seattle, Washington, USA. princep@amgen.com
Background:
Quantitating levels of therapeutic proteins in serum or plasma is critical for determining exposure levels and establishing pharmacokinetic parameters. Traditionally, whole blood is not used, mostly due to its inability to be frozen and potential issues with assay interference. To investigate the ability to reproducibly quantitate therapeutic antibodies present in dried blood spots (DBS) compared with a typical serum sample-based method, we used ELISA and electrochemiluminescence immunoassays to measure therapeutic drug levels present in DBS samples.
Results:
Measurements of antibody therapeutics in DBS were reproducible, yielding methods that are precise, accurate and met expected sensitivity requirements compared with plasma-based methods.
Conclusions:
DBS are a viable alternative to the use of conventional serum or plasma samples for quantitative therapeutic antibody measures.
More Related Videos
08:21Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013